Biotech News
Related news
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FATEFate Therapeutics2026-07-01 20:05 EST
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
MMSIMerit Medical2026-08-05 16:00 EST
Merit Medical to Participate in Upcoming Investors Conferences in August
REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST
Regeneron Announces Investor Conference Presentations
ZNTLZentalis2026-07-17 20:15 EST
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
FATEFate Therapeutics2026-07-06 12:30 EST
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
REPLReplimune Group2026-07-30 22:15 EST
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
IN8bio
Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...
Recent company news
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INABIN8bio2026-07-09 12:00 EST
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
INABIN8bio2026-06-03 12:30 EST
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
INABIN8bio2026-06-01 12:30 EST
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Stock data
- Close
- 1.28 USD
- Market cap
- 14.96M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States